Fibroblast Growth Factor 23, Klotho, and Disordered Mineral Metabolism in Chronic Kidney Disease: Unraveling the Intricate Tapestry of Events and Implications for Therapy

Journal of Renal Nutrition

Volumn 23, Issue 3, 2013, Pages 250-254

  Gutiérrez, Orlando M ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MINERAL; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; GENETICS; HOMEOSTASIS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHOSPHATE INTAKE; REVIEW;

CARDIOVASCULAR DISEASES; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HOMEOSTASIS; HUMANS; MINERALS; PARATHYROID HORMONE; PHOSPHATES; PHOSPHORUS, DIETARY; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D;

EID: 84876701999     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2013.01.024     Document Type: Review

References (36)

1. Quarles L.D. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 2012, 8:276-286.
2. Saito H., Kusano K., Kinosaki M., et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 2003, 278:2206-2211.
3. Bowe A.E., Finnegan R., Jan de Beur S.M., et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001, 284:977-981.
4. Liu S., Tang W., Zhou J., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006, 17:1305-1315.
5. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117:4003-4008.
6. Hasegawa H., Nagano N., Urakawa I., et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010, 78:975-980.
7. Shalhoub V., Shatzen E.M., Ward S.C., et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012, 122:2543-2553.
8. Gonzalez-Parra E., Gonzalez-Casaus M.L., Galan A., et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 2011, 26:2567-2571.
9. Moe S.M., Zidehsarai M.P., Chambers M.A., et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:257-264.
10. Oliveira R.B., Cancela A.L., Graciolli F.G., et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?. Clin J Am Soc Nephrol 2010, 5:286-291.
11. Matsumura Y., Aizawa H., Shiraki-Iida T., Nagai R., Kuro-o M., Nabeshima Y. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun 1998, 242:626-630.
12. Alexander R.T., Woudenberg-Vrenken T.E., Buurman J., et al. Klotho prevents renal calcium loss. J Am Soc Nephrol 2009, 20:2371-2379.
13. Hu M.C., Shi M., Zhang J., et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010, 24:3438-3450.
14. Aizawa H., Saito Y., Nakamura T., et al. Downregulation of the Klotho gene in the kidney under sustained circulatory stress in rats. Biochem Biophys Res Commun 1998, 249:865-871.
15. Hu M.C., Shi M., Zhang J., Quinones H., Kuro-o M., Moe O.W. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 2010, 78:1240-1251.
16. Sugiura H., Yoshida T., Shiohira S., et al. Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. Am J Physiol Renal Physiol 2012, 302:F1252-F1264.
17. Koh N., Fujimori T., Nishiguchi S., et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001, 280:1015-1020.
18. Lim K., Lu T.S., Molostvov G., et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012, 125:2243-2255.
19. Hu M.C., Shi M., Zhang J., et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011, 22:124-136.
20. Fliser D., Kollerits B., Neyer U., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007, 18:2600-2608.
21. Gutierrez O.M., Mannstadt M., Isakova T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359:584-592.
22. Isakova T., Xie H., Yang W., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011, 305:2432-2439.
23. Seiler S., Reichart B., Roth D., Seibert E., Fliser D., Heine G.H. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transpl 2010, 25:3983-3989.
24. Jean G., Terrat J.C., Vanel T., et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transpl 2009, 24:2792-2796.
25. Kendrick J., Cheung A.K., Kaufman J.S., et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011, 22:1913-1922.
26. Faul C., Amaral A.P., Oskouei B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
27. Gutierrez O.M., Januzzi J.L., Isakova T., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119:2545-2552.
28. Mirza M.A., Larsson A., Melhus H., Lind L., Larsson T.E. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009, 207:546-551.
29. Kanbay M., Nicoleta M., Selcoki Y., et al. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol 2010, 5:1780-1786.
30. Mirza M.A., Hansen T., Johansson L., et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transpl 2009, 24:3125-3131.
31. Mirza M.A., Larsson A., Lind L., Larsson T.E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009, 205:385-390.
32. Saito Y., Yamagishi T., Nakamura T., et al. Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 1998, 248:324-329.
33. Nagai R., Saito Y., Ohyama Y., et al. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci 2000, 57:738-746.
34. Saito Y., Nakamura T., Ohyama Y., et al. In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun 2000, 276:767-772.
35. Smith R.C., O'Bryan L.M., Farrow E.G., et al. Circulating αKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest 2012, 122:4710-4715.
36. Marsell R., Krajisnik T., Goransson H., et al. Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23. Nephrol Dial Transpl 2008, 23:827-833.